文献速递淋巴瘤

STAT6突变补偿CREBBP突变并过度激活滤泡性淋巴瘤中IL4/STAT6/RRAGD/mTOR信号

STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma.
PubMed 文献 · Leukemia · 2025-02-05

该研究基于RNA-seq基因表达数据,比较正常人淋巴结来源B淋巴细胞(N=6)、STAT6野生型滤泡性淋巴瘤(N=11)和STAT6突变型滤泡性淋巴瘤(N=4)在IL4刺激前后的表达谱。发现STAT6突变广泛增强IL4诱导的基因表达,而野生型STAT6滤泡性淋巴瘤中IL4/JAK/STAT6反应减弱与共存CREBBP突变相关。IL4诱导的RRAGD表达为淋巴瘤细胞mTOR激活所必需,CREBBP突变减弱而STAT6突变增强IL4和BCR诱导的mTOR激活。

要点

  • STAT6突变型滤泡性淋巴瘤中IL4诱导的基因表达广泛增强。
  • 野生型STAT6滤泡性淋巴瘤的IL4/JAK/STAT6反应减弱与CREBBP突变共存相关。
  • IL4诱导RRAGD表达,RRAGD为淋巴瘤细胞mTOR激活所必需。

核心结论

  • STAT6突变可补偿CREBBP突变导致的IL4/JAK/STAT6反应减弱,并过度激活IL4/STAT6/RRAGD/mTOR信号。

研究设计与样本

  • 基于RNA-seq的基因表达研究,纳入正常人淋巴结来源B淋巴细胞(N=6)、STAT6野生型滤泡性淋巴瘤(N=11)和STAT6突变型滤泡性淋巴瘤(N=4),在IL4体外刺激前后进行比较。

主要发现

  • STAT6突变导致IL4诱导的基因表达广泛增强。
  • 与正常B淋巴细胞或STAT6突变型滤泡性淋巴瘤相比,STAT6野生型滤泡性淋巴瘤的基线及IL4诱导的基因表达水平降低。
  • IL4/JAK/STAT6反应减弱与共存的CREBBP突变相关,实验验证完整的CREBBP为许多IL4诱导基因的诱导所必需。
  • IL4处理诱导RRAGD表达,RRAGD为淋巴瘤细胞mTOR激活所必需,IL4增强的BCR信号诱导mTOR激活。
  • CREBBP突变减弱而STAT6突变增强IL4和BCR诱导的mTOR激活。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activating mutations in STAT6 are common in Follicular Lymphoma (FL) and transformed FL and various other B cell lymphomas. Here, we report RNA-seq based gene expression data on normal human lymph node derived B lymphocytes (NBC; N = 6), and primary human FL WT (N = 11) or mutant (N = 4) for STAT6 before and after ex vivo stimulation with IL4. We found that STAT6 mutants result in broad based augmentation of IL4-induced gene expression. Unexpectedly, in FL with WT STAT6 we measured reduced baseline and IL4-induced gene expression levels when compared with NBC lymphocytes or FL with STAT6 mutations. We tracked the attenuated IL4/JAK/STAT6 response to co-existing CREBBP mutations and experimentally verified that intact CREBBP is required for the induction of many IL4-induced genes. One of the IL4-induced genes here identified is RRAGD, a small G-protein involved in lysosomal mTOR activation. We show that IL4 treatment induced RRAGD expression, that RRAGD is required for mTOR activation in lymphoma cells and that IL4-enhanced BCR signaling induced mTOR activation. The IL4 and BCR-induced mTOR activation was reduced by CREBBP mutants and augmented by mutant STAT6, establishing a link between STAT6 mutations and mTOR regulated pro-growth pathways in lymphoma.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Shao Q, Bedi K, Malek IA, et al. STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma. Leukemia. 2025. PMID: 39910284. doi:10.1038/s41375-025-02525-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。